CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 128 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2023. The put-call ratio across all filers is 1.90 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,210,602 | -30.9% | 2,529,116 | +0.6% | 1.48% | -22.2% |
| Q2 2023 | $79,917,390 | +30.3% | 2,513,916 | 0.0% | 1.90% | +29.9% |
| Q1 2023 | $61,314,411 | -22.4% | 2,513,916 | +0.3% | 1.46% | -23.1% |
| Q4 2022 | $79,053,875 | +11.9% | 2,506,464 | +0.3% | 1.90% | +4.3% |
| Q3 2022 | $70,626,000 | +51.2% | 2,499,148 | +41.4% | 1.82% | +34.1% |
| Q2 2022 | $46,723,000 | -22.6% | 1,767,141 | +2.5% | 1.36% | -10.5% |
| Q1 2022 | $60,334,000 | +12.9% | 1,723,341 | +4.5% | 1.52% | +23.0% |
| Q4 2021 | $53,442,000 | +13.2% | 1,648,435 | +3.0% | 1.24% | +24.4% |
| Q3 2021 | $47,217,000 | +81.2% | 1,600,589 | +57.4% | 0.99% | +92.8% |
| Q2 2021 | $26,054,000 | +88.8% | 1,016,945 | +1.2% | 0.52% | +71.1% |
| Q1 2021 | $13,800,000 | -16.7% | 1,005,100 | +0.6% | 0.30% | -14.2% |
| Q4 2020 | $16,563,000 | – | 999,000 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |